


Effects of antiviral therapy and drug withdrawal on postpartum hepatitis in pregnant women with chronic HBV infection

Minghui Li^{1,2}  · Fangfang Sun¹ · Xiaoyue Bi¹ · Yanjie Lin² · Liu Yang¹ · Tingting Jiang¹ · Wen Deng¹ · Yao Lu¹ · Lu Zhang¹ · Wei Yi³  · Yao Xie^{1,2} 

Received: 3 June 2022 / Accepted: 13 August 2022
© Asian Pacific Association for the Study of the Liver 2022

Abstract

Objective To investigate the effect of antiviral therapy and drug withdrawal on the incidence of hepatitis B after delivery in pregnant women with chronic hepatitis B virus (CHB) infection who received tenofovir disoproxil fumarate (TDF) treatment.

Methods

pregnant women are reluctant to take antiviral drugs because of concerns about the safety of breastfeeding. A considerable proportion of patients with chronic HBV infection have postpartum hepatitis after delivery, with a proportion as high as 50% [11], especially within 6 months after delivery [12], and some patients present with severe chronic hepatitis B and liver failure [13]. Our previous findings suggest that HBV DNA positivity at delivery and postpartum alanine aminotransferase (ALT) elevation in chronic HBV infection patients without antiviral therapy are independent predictors of acute exacerbation of chronic hepatitis B [14]. However, the predictors of acute exacerbation of chronic hepatitis B after short-term antiviral therapy in pregnant women with chronic HBV infection are still limited. Whether withdrawal of antiviral therapy after delivery will affect the occurrence of postpartum hepatitis is unclear. In this study, we observed the incidence of postpartum hepatitis in pregnant women with chronic HBV infection who were treated with or without antiviral drugs, and explored the impact of different timing of stopping antiviral treatment on the occurrence of hepatitis after delivery.

Some studies reported the recurrence of postpartum hepatitis in patients with chronic HBV infection, focusing on the blocking effect of antiviral therapy during pregnancy on mother-to-child transmission of HBV [15–19]. In these studies, inconsistent timing of postpartum drug discontinuation among pregnant women might influence the development of postpartum hepatitis [15–19]. We published a large sample retrospective study in 2018 showing that abnormal postnatal liver function was common in both non-HBV-infected and HBV-infected women, and abnormal postnatal liver function in HBV-infected women occurred in those with viral load greater than 10^6 IU/ml [14]. Currently, there are few studies on the occurrence and influencing factors of postpartum hepatitis in pregnant women with chronic HBV infection. In this prospective study, we studied the occurrence of postpartum hepatitis in untreated pregnant women with chronic HBV infection, pregnant women who received TDF treatment for the prevention of mother-to-child transmission of HBV during pregnancy and stopped treatment immediately after delivery or 6 weeks after delivery. The results will more accurately reveal the effect of TDF treatment and drug withdrawal during pregnancy on the occurrence of postpartum hepatitis.

Patients and methods

Subjects and study design

This is a prospective observational cohort study of HBeAg-positive and HBV-DNA positive pregnant women. Eligible mothers with chronic HBV infection who underwent

prenatal examination and delivered at Beijing Ditan Hospital between January 1, 2017 and December 30, 2019 were enrolled. This study was approved by the Ethics Committee of Beijing Ditan Hospital Affiliated to Capital University of Medical Sciences (Jing Di Lun Ke Zi 2017 No. 004-02), and was registered with Clinical Trials (NCT03214302).

Inclusion criteria were: HBeAg positive and HBV DNA $> 10^6$ IU/ml; No anti HBV drugs were taken before entering the group; No pregnancy induced hypertension, premature rupture of membranes, prenatal bleeding and other diseases; No history of amniocentesis during pregnancy; No other virus infections (HCV, HIV, CMV, *etc*); No hepatic fibrosis and cirrhosis.

After enrollment, pregnant women were divided into groups according to their willingness to receive antiviral treatment or not. The group without antiviral treatment during pregnancy was set as control. In the treated group, tenofovir dipivoxil antiviral therapy was started at 32 weeks of gestation and discontinued immediately or at 6 weeks after delivery. Adverse reactions, especially renal impairment, were closely monitored during TDF antiviral therapy.

Both Chinese and American guidelines recommended 24 weeks of postpartum follow-up for all HBV-infected mothers [20, 21]. Delivery and pregnancy complications were examined at 6 weeks postpartum. Blood routine examination, liver function, renal function, coagulation and other biochemical indicators, serum HBV DNA content and serological indicators were examined at 6 weeks, 12 weeks, and 24 weeks postpartum. Liver function was rechecked 1 month later in patients with ALT > 40 U/L at 12 weeks postpartum.

Definition of the onset of hepatitis after drug withdrawal was: ALT is 2 times higher than the upper limit of normal (40 U/L), HBV DNA is positive, and other diseases leading to abnormal liver function are excluded. $5 \text{ ULN} \leq \text{ALT} < 10 \text{ ULN}$ (normal ALT ≤ 40 U/L) is defined as ALT flare, and $\text{ALT} \geq 10 \text{ ULN}$ is defined as ALT exacerbation [22].

All newborns born to mothers with chronic HBV infection were injected with HBIG 200 IU and 10 micrograms of hepatitis B vaccine within 2 hours of birth, and then injected with 10 micrograms again at 1 and 6 months of birth.

Biochemical examination

HBV DNA, HBsAg, HBeAg and liver function were detected at 30–32 weeks of pregnancy, 4 weeks of antiviral therapy, before delivery and 2, 6, 12 and 24 weeks after delivery. Liver function and renal function were detected by Hitachi automatic biochemical analyzer. Serum HBV DNA load was detected by Roche (Cobas AmpliPrep/Cobas TaqMan 96) automatic real-time fluorescence quantitative PCR detection reagent (detection limit: 20 IU/ml); HBsAg/anti-HBs level and HBeAg/anti-HBe were detected by Abbott architect i2000 microparticle chemiluminescence

reagent. The detection range of HBsAg level was 0.05–250 IU/ml. If the HBsAg level was greater than 250 IU/ml, it'd be automatically diluted 500 times. The actual HBsAg level was calculated by multiplying the test value by 500. HBsAg < 0.05 IU/ml was defined as the disappearance of HBsAg.

Statistical analysis

The continuous variables were described by mean, standard deviation, maximum, minimum, median and interquartile range. The classified data are statistically described by frequency and rate. Chi-square analysis, Fisher test, *t* test and Wilcoxon nonparametric test were used for comparison between groups.

Chi-square test, Mantel–Haenszel hierarchical analysis, trend chi-square analysis, and analysis of covariance were used to find the correlation with the occurrence of hepatitis after drug withdrawal.

Because there are many factors affecting the failure of HBV mother-to-child transmission interruption and the occurrence of hepatitis after delivery, unconditional logistic regression analysis was conducted, in which the success of HBV mother-to-child transmission interruption or the occurrence of hepatitis is taken as the dependent variable, and study factors are taken as the independent variables. Stepwise regression method was used for variable selection.

Results

Patient enrollment and deposition

A total of 397 HBeAg-positive pregnant women with chronic HBV infection and age 30.74 ± 3.85 years were enrolled during the study, of whom 112 received no antiviral treatment (Control group) and 251 were treated with tenofovir dipivoxil (Treated group). In the Control group, 106 women delivered and 96 were followed up till the onset of postpartum hepatitis or till 24 weeks postpartum. In the Treated group, 232 delivered and 168 were followed up till the onset of postpartum hepatitis or till 24 weeks postpartum. Among them, 131 cases stopped taking drug immediately after delivery and 37 cases stopped taking drug 6 weeks after delivery (Fig. 1). All subjects enrolled in this study were HBeAg-positive pregnant women. They could hardly recall their hepatitis B vaccination status a long time ago.

Changes of biochemical indexes and HBV DNA during pregnancy

There was no difference in clinical biochemical parameters between the two groups at baseline. The HBV DNA content

in Treated group was significantly lower than that in Control group at 4 weeks of antiviral treatment and before delivery, suggesting that tenofovir dipivoxil had good antiviral effect (Table 1).

Changes of HBV DNA content during pregnancy and after delivery

A total of 264 pregnant women were followed up for HBV DNA levels after delivery, 96 (36.4%) of whom were in the Control group and 168 (63.6%) were treated with tenofovir dipivoxil.

The HBV DNA content in the Control group remained at a relatively stable high level during pregnancy and after delivery. In the Treated group, HBV DNA decreased significantly at 4 weeks of treatment and continued to decrease during pregnancy. The virus quickly rebounded to high levels after 6 weeks of discontinuation (Table 2). However, there was still a decrease in overall viral levels compared with baseline (Fig. 2), owing to occurrence of hepatitis in some patients.

Occurrence of postpartum hepatitis and treatment

A total of 67 patients' ALT reached the diagnostic level of hepatitis after delivery, including 28.1% (27/96) of patients in the Control group and 23.8% (40/168) in the Treated group (Table 3). There was no significant difference between the two groups ($p > 0.1$). There was also no significant difference in the incidence and prevalence of hepatitis between patients with immediate withdrawal and delayed treatment withdrawal. 96.3% of postpartum hepatitis in control group and 92.3% of postpartum hepatitis in immediate drug withdrawal group occurred within 12 weeks after delivery. While patients stopped taking drug 6 weeks after delivery, 77.7% of Hepatitis occurred within 12 weeks after delivery. There was not significant difference of the rates of postpartum hepatitis occurred within 12 weeks after delivery ($\chi^2 = 2.876$, $p = 0.237$) (Table 4).

$5 \text{ ULN} \leq \text{ALT} < 10 \text{ ULN}$ (normal $\text{ALT} \leq 40 \text{ U/L}$) is defined as ALT flare, and $\text{ALT} \geq 10 \text{ ULN}$ is defined as ALT exacerbation [22]. Among patients who developed postpartum hepatitis, ALT flare occurred in 7 cases (25.92%) in the control group, 9 cases (29.03%) in the immediate withdrawal group and 1 case (11.11%) in the delayed withdrawal group ($\chi^2 = 1.190$, $p = 0.551$). ALT exacerbation was observed in 3 (11.11%) cases, 2 (6.45%) cases, and 1 (11.11%) case, respectively ($\chi^2 = 0.444$, $p = 0.801$). Bilirubin levels were normal in all patients with postpartum hepatitis and no patients had severe hepatitis. A total of 60 patients were treated with antiviral therapy after the diagnosis of hepatitis, including 32 patients




Fig. 1 Patient enrollment and disposition

treated with TDF and 28 patients treated with PEG-IFN or PEG-IFN combined with TDF.

The results of logistic regression analysis showed that the occurrence of hepatitis after delivery was not related to the patient's age, antiviral treatment, DNA content before enrollment and before delivery, and whether to stop antiviral drug immediately (Table 5).

HBV markers at birth and blocking effect of HBV mother-to-child transmission in newborns

A total of 346 newborns were delivered, including 189 males and 157 females, with body length 50.07 ± 1.07 cm, weight 3311.78 ± 424.04 g, Apgar1 score 9.97 ± 0.26 , Apgar 5

score 9.99 ± 0.22 , Apgar 10 score 10.00 ± 0.00 . There were 7 cases of fetal malformation, including 5 cases of syndactyl, 1 case of genital malformation and 1 case of cryptorchidism. In 326 patients who obtained HBV serum markers in venous blood at birth, 41.4% (135) were HBsAg positive (HBsAg > 0.05 IU/ml) and HBsAg level was 0.14 (0.08, 0.41) IU/ml. 96.3% (314) were HBeAg positive (HBeAg > 1.0 S/CO), the HBeAg level was 64.46(18.15, 169.72) S/CO. 98.5% were anti-HBe negative (anti-HBe > 1.0 S/CO). 98.5% (321) were anti-HBc positive (anti-HBc > 1.0 S/CO). Serum HBV DNA content was detected in 321 cases, 14.0% positive (HBV DNA ≥ 20 IU/ml), and HBV DNA content was 3.47 ± 1.33 log IU/ml.

Table 1 Clinical biochemical parameters during pregnancy

| | Baseline enrollment (31–32 weeks of gestation) | | | | After enrollment (antiviral therapy 4 w) | | | | Before delivery | | | | | |
|-----------------------------------|--|----------------|---------|---------|--|-----------------|---------|---------|-----------------|----------------|---------|---------|--------|---------|
| | Control | | Treated | | Control | | Treated | | Control | | Treated | | T test | p value |
| | | | | | | | | | | | | | | |
| Age(years) | 29.99 ± 3.60 | 31.35 ± 3.95 | 2.805 | 0.005 / | 29.99 ± 3.60 | 31.35 ± 3.95 | 2.805 | 0.005 / | 29.99 ± 3.60 | 31.35 ± 3.95 | 2.805 | 0.005 / | | |
| HBV DNA (log ₁₀ IU/mL) | 7.99 ± 0.62 | 8.03 ± 0.51 | 0.676 | 0.500 | 7.55 ± 0.80 | 5.20 ± 0.72 | -9.910 | <0.001 | 7.87 ± 1.20 | 4.50 ± 1.03 | -23.928 | <0.001 | | |
| HBeAg-positive, % | 100% | 100% | - | 100% | 100% | 100% | - | 100% | 100% | 100% | - | 100% | | |
| ALT (U/L) | 22.17 ± 14.80 | 23.46 ± 20.03 | 0.051 | 0.960 | 20.71 ± 27.69 | 23.75 ± 18.81 | 1.050 | 0.295 | 18.41 ± 11.80 | 20.30 ± 9.73 | 1.770 | 0.078 | | |
| AST (U/L) | 21.60 ± 14.61 | 22.44 ± 6.21 | 0.239 | 0.812 | 20.85 ± 13.03 | 23.63 ± 11.04 | 2.091 | 0.038 | 21.47 ± 9.22 | 22.72 ± 6.29 | 2.105 | 0.036 | | |
| TBIL (μmol/L) | 7.11 ± 2.41 | 7.74 ± 2.59 | 1.909 | 0.057 | 7.62 ± 3.44 | 7.99 ± 2.56 | 0.932 | 0.352 | 7.29 ± 2.68 | 7.48 ± 2.66 | 0.321 | 0.748 | | |
| DBIL (μmol/L) | 1.72 ± 0.76 | 1.771.23 | 0.157 | 0.875 | 1.70 ± 1.03 | 1.91 ± 0.87 | 1.396 | 0.164 | 1.68 ± 1.26 | 1.72 ± 0.82 | 0.062 | 0.951 | | |
| ALB (g/L) | 39.03 ± 3.28 | 37.09 ± 2.07 | -5.525 | <0.001 | 36.75 ± 2.44 | 36.24 ± 2.66 | -2.714 | 0.008 | 35.77 ± 2.86 | 35.86 ± 3.06 | -0.446 | 0.656 | | |
| GGT (U/L) | 10.15 ± 7.81 | 9.60 ± 6.73 | -0.957 | 0.339 | 9.79 ± 6.77 | 9.37 ± 5.61 | -0.997 | 0.320 | 10.06 ± 5.47 | 9.29 ± 4.86 | -0.273 | 0.786 | | |
| ALP (U/L) | 70.55 ± 34.25 | 76.80 ± 23.13 | 1.600 | 0.112 | 129.88 ± 52.41 | 149.66 ± 346.69 | 0.607 | 0.545 | 140.52 ± 32.73 | 159.07 ± 51.51 | 1.797 | 0.078 | | |
| TBA (μmol/L) | 3.25 ± 2.60 | 4.11 ± 8.91 | 0.531 | 0.596 | 3.70 ± 3.35 | 7.66 ± 41.40 | 0.902 | 0.368 | 8.90 ± 7.71 | 78.36 ± 536.73 | -1.155 | 0.253 | | |
| BUN (μmol/L) | 3.08 ± 0.78 | 3.96 ± 11.64 | 0.662 | 0.509 | 2.92 ± 0.62 | 3.10 ± 0.80 | 0.994 | 0.321 | 3.91 ± 3.35 | 3.64 ± 0.90 | -1.147 | 0.252 | | |
| Cr (μmol/L) | 44.33 ± 5.78 | 45.63 ± 11.95 | 0.530 | 0.597 | 46.67 ± 5.19 | 50.90 ± 23.20 | 0.890 | 0.375 | 50.53 ± 8.63 | 55.51 ± 41.58 | 1.166 | 0.245 | | |
| PHOS (mmol/L) | 1.11 ± 0.10 | 1.18 ± 0.65 | 0.865 | 0.388 | 1.15 ± 0.13 | 1.13 ± 0.13 | -1.075 | 0.284 | 1.13 ± 0.15 | 1.10 ± 0.17 | -1.382 | 0.168 | | |
| PTA (%) | 109.99 ± 13.45 | 113.40 ± 10.34 | 2.089 | 0.041 | 116.68 ± 9.95 | 116.79 ± 10.59 | 0.102 | 0.919 | 117.03 ± 17.82 | 111.41 ± 15.73 | -2.732 | 0.007 | | |
| INR | 0.97 ± 0.05 | 1.35 ± 6.00 | 0.498 | 0.619 | 0.96 ± 0.05 | 0.93 ± 0.05 | -2.019 | 0.045 | 0.94 ± 0.04 | 0.96 ± 0.06 | 0.743 | 0.458 | | |

No es: HBV DNA: hepatitis B virus deoxyribose nucleic acid; HBeAg: hepatitis B e antigen; ALT: alanine aminotransferase; AST: aspartate aminotransferase; TBil: total bilirubin; DBil: direct bilirubin; ALB: Albumin; GGT: glutamyl transpeptidase; ALP: alkaline phosphatase; TBA: total bile acid; BUN: urea nitrogen; Cr: creatinine; PHOS: phosphorus; PTA: prothrombin time activity; INR: international normalized ratio

Table 2 HBV DNA levels in HBV-positive patients during pregnancy and after delivery

| HBV DNA level (log ₁₀ IU/mL) | Control | Immediate withdrawal | Delayed withdrawal | <i>T</i> test/ <i>p</i> value Control vs. Immediate withdrawal | <i>T</i> test/ <i>p</i> value Control vs. Delayed withdrawal | <i>T</i> test/ <i>p</i> value Immediate withdrawal vs. Delayed withdrawal |
|---|-------------|----------------------|--------------------|--|--|---|
| Before antiviral therapy | 7.99 ± 0.62 | 8.05 ± 0.51 | 7.98 ± 0.52 | -0.708/0.479 | 0.077/0.939 | 0.648/0.518 |
| 4 weeks after antiviral therapy | 7.55 ± 0.80 | 5.24 ± 0.62 | 5.21 ± 0.94 | 11.226/<0.001 | 6.966/<0.001 | 0.207/0.837 |
| Before delivery | 7.87 ± 1.20 | 4.51 ± 0.99 | 4.53 ± 0.96 | 22.875/<0.001 | 15.275/<0.001 | -0.016/0.987 |
| 6 weeks after delivery | 7.87 ± 0.93 | 7.98 ± 0.73 | 4.80 ± 1.79 | -0.866/0.388 | 9.339/<0.001 | 10.212/<0.001 |
| 12 weeks after delivery | 7.41 ± 1.50 | 7.83 ± 1.21 | 7.43 ± 1.55 | -1.276/0.211 | -0.049/0.961 | 1.336/0.184 |
| 24 weeks after delivery | 7.13 ± 2.11 | 7.34 ± 2.03 | 7.10 ± 2.13 | -0.535/0.593 | 0.056/0.956 | 0.476/0.635 |

No es: Control: no antiviral treatment during pregnancy

Immediate withdrawal: withdrawal of antiviral drugs immediately after delivery

Delayed withdrawal: withdrawal of antiviral drugs at 6 weeks after delivery




Fig. 2 Changes of HBV DNA content in pregnant women infected with HBV during pregnancy and postpartum

All newborns in this study received anti-HBV HBIG 100 IU injection and 10 µg hepatitis B vaccine within 6 hours after birth, and returned to the community to receive hepatitis B vaccine at 1 and 6 months after birth. In this study, a total of 262 newborns received the follow-up results of blocking HBV mother-to-child transmission, and the success rates of blocking was significantly different in the treatment group (155/156, 99.35%) and the control group (96/106, 90.56%) ($\chi^2=12.132$, $p < 0.001$).

Discussion

Guidelines recommend short-course antiviral therapy to reduce the risk of mother-to-child transmission of chronic hepatitis B virus in pregnant women with high viral load [5, 8–10, 23]. Unfortunately, some patients have postpartum chronic hepatitis B after the end of short-course antiviral therapy. The aim of the study was to examine the timing of

Table 3 Incidence of postpartum hepatitis in different population groups

| | Control (n = 96) | Immediate withdrawal (n = 131) | Delayed withdrawal (n = 37) | χ^2/p value control vs. immediate withdrawal | χ^2/p value control vs. delayed withdrawal | χ^2/p value immediate withdrawal vs. delayed withdrawal | χ^2/p value Control vs. Treated |
|-----------------------------|------------------|--------------------------------|-----------------------------|---|---|--|--------------------------------------|
| Incidence of hepatitis% (n) | 28.1% (27) | 23.7% (31) | 24.3% (9) | 0.580/0.446 | 0.195/0.658 | 0.007/0.934 | 0.601/0.438 |

Notes: Control: no antiviral treatment during pregnancy

Immediate withdrawal: withdrawal of antiviral drugs immediately after delivery

Delayed withdrawal: withdrawal of antiviral drugs at 6 weeks after delivery

drug withdrawal on occurrence of hepatitis after delivery in pregnant women with chronic HBV infection.

Antiviral therapy during pregnancy is an important measure to improve the blocking rate of mother-to-child transmission of HBV. However, HBV infected pregnant women with significant hepatitis, liver fibrosis or cirrhosis during pregnancy must continue antiviral therapy even after delivery, so we excluded these patients from our study [20, 21, 24, 25]. Currently, there is no consensus on when to stop antiviral drugs after delivery and its effect on the occurrence of postpartum hepatitis in these pregnant women who take antiviral drugs during pregnancy to prevent mother-to-child transmission of HBV [20, 21, 24, 25]. The aim of this study was to investigate the effect of withdrawal of TDF after delivery on the occurrence of postpartum hepatitis and hepatitis development in pregnant women who had been using TDF for prevention of HBV mother-to-child transmission during pregnancy, thus HBV-infected pregnant women with significant hepatitis, liver fibrosis or cirrhosis during pregnancy were excluded. Meanwhile, in order to reduce the pregnancy complications (such as gestational hypertension) and delivery complications (such as postpartum hemorrhage) on the safety of TDF use, occurrence of postpartum hepatitis and deterioration of liver function, patients with gestational hypertension, premature rupture of membranes, prenatal bleeding and other pregnancy and/or delivery complications were excluded in this study. Patients with other causes of liver disease, liver fibrosis and cirrhosis were also excluded. Adverse reactions, especially renal impairment, were closely monitored during TDF antiviral therapy.

TDF is recommended as the first choice for preventing mother-to-child transmission of HBV because it can effectively inhibit HBV replication, with little drug resistance and high safety in pregnancy [25, 26]. Studies have shown that on the basis of regular neonatal immunization, if the serum HBV DNA of pregnant women was reduced to 10^6 IU/ml before delivery, the mother-to-child transmission of HBV could be effectively blocked [27–30]. Some studies did not recommend antiviral therapy during pregnancy for blocking mother-to-child transmission of HBV in pregnant women with HBVDNA < 10^6 IU/ml [31]. Although most current guidelines recommend antiviral therapy for prevention of mother-to-child transmission of HBV from 28 weeks of gestation, TDF can reduce HBV DNA by more than 3 log (HBV DNA < 10^6 IU/ml) in pregnant women after 4 weeks of treatment due to its strong inhibition of virus replication [32]. To minimize the risk of fetal exposure to TDF and reduce the side effects of drugs on pregnant women, antiviral therapy was started at 32 weeks of gestation in this study.

Our study results showed that the success rate of mother-to-child block in tenofovir group at 32 weeks of gestation was 99.35%, which was significantly higher than that in Control group (90.56%). At the same time, HBV DNA

levels were significantly lower in the treated group at 4

during pregnancy, HBV DNA level before delivery and the time of drug withdrawal.

In conclusion, withdraw of antiviral treatment immediately or at 6 weeks after delivery did not affect the incidence of hepatitis after delivery. Above 90% of hepatitis occurred within 12 weeks after delivery in those without antiviral treatment and who immediately stopped antiviral treatment after delivery. Delaying drug withdrawal might delay the onset of postpartum hepatitis. Our results also suggest that postpartum or 12 weeks after drug withdrawal is the key follow-up period to monitor the occurrence of hepatitis. However, due to the number of completed follow-up subjects is limited in this study, the conclusions need to be further verified. What's more, because monitoring for only 24 weeks after delivery may overlook the incidence of late flare, it's recommended to observe the incidence of hepatitis at 48 weeks of postpartum in future studies.

Acknowledgements The authors thank all study patients and staffs participating in the study.

Author contributions ML and YX contributed to the study design and the data analysis. ML, WY, and YX contributed to the recruitment, enrolment, and assessment of participants, as well as data collection. LZ, YL, FS, YL, LY, and WD contributed to following up with the patients. XB, TJ, and LY managed all aspects of laboratory support. ML wrote the first draft of the manuscript. YX revised the manuscript. YX is the guarantor of the article. All authors approved the final version of the manuscript.

Funding This study was funded in part by the Beijing Hospitals Authority Clinical medicine Development of special funding support (No. XMLX 202127), National Science and Technology Major Project of China (No. 2017ZX10201201-001-006, 2017ZX10201201-002-006, 2018ZX10715-005-003-005), The Digestive Medical Coordinated Development Center of Beijing Hospitals Authority (No. XXZ0302 and XXT28), Special Public Health Project for Capital Health Development (No. 2022-1-2172), Project supported by Beijing science and technology commission (No. Z211100002921059), and High-level Public Health Technical Personnel Training Program of Beijing Municipal Health Commission (No. 2022-3-050).

Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request.

Declarations

Conflict of interest Minghui Li, Fangfang Sun, Xiaoyue Bi, Yanjie Lin, Liu Yang, Tingting Jiang, Wen Deng, Yao Lu, Lu Zhang, Wei Yi and Yao Xie have no conflict of interest.

Ethics approval This study was approved by the Ethics Committee of Beijing Ditan Hospital Affiliated to Capital University of Medical Sciences (Jing Di Lun Ke Zi 2017 No. 004-02), and was registered with Clinical Trials (NCT03214302).

Informed consent These patients were fully informed of the risks and signed informed consent.

References

1. Kafeero HM, Ndagire D, Ocamo P, Kudamba A, Walusansa A, Sendagire H. Prevalence and predictors of hepatitis B virus (HBV) infection in east Africa: evidence from a systematic review and meta-analysis of epidemiological studies published from 2005 to 2020. *Arch Public Health*. 2021;79:167
2. World Health O. Hepatitis B vaccines: WHO position paper, July 2017 - Recommendations. *Vaccine*. 2019;37:223–225
3. Akoury T, Whetstone DR: Splenic Rupture. In: *StatPearls*. Treasure Island (FL), 2022.
4. Sandmann L, Cornberg M. HCC and HBV reactivation-A preventable condition not to be missed. *Hepatology*. 2022;75:1075–1077
5. Wang G, Duan Z. Guidelines for prevention and treatment of chronic hepatitis B. *J Clin Transl Hepatol*. 2021;9:769–791
6. Wang M, Wang Y, Feng X, Wang R, Wang Y, Zeng H, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: experience of the Chinese National Cancer Center. *Int J Infect Dis*. 2017;65:15–21
7. Zhou J, Sun H, Wang Z, Cong W, Wang J, Zeng M, Zhou W, et al. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (2019 Edition). *Liver Cancer* 2020;9:682–720.
8. Terrault NA, Lok ASF, McMahon BJ, Chang KM, Hwang JP, Jonas MM, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. *Hepatology*. 2018;67:1560–1599
9. Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B Virus: Advances in prevention, diagnosis, and therapy. *Clin Microbiol Rev* 2020;33.
10. Shah NJ, Aloysius MM, Sharma NR, Pallav K. Advances in treatment and prevention of hepatitis B. *World J Gastrointest Pharmacol Ther*. 2021;12:56–78
11. Kushner T, Shaw PA, Kalra A, Magaldi L, Monpara P, Bedi G, et al. Incidence, determinants and outcomes of pregnancy-associated hepatitis B flares: A regional hospital-based cohort study. *Liver Int*. 2018;38:813–820
12. Chang CY, Aziz N, Poongkunran M, Javaid A, Trinh HN, Lau DT, et al. Serum aminotransferase flares in pregnant and postpartum women with current or prior treatment for chronic hepatitis B. *J Clin Gastroenterol*. 2018;52:255–261
13. Joshi SS, Coffin CS. Hepatitis B and pregnancy: virologic and immunologic characteristics. *Hepatol Commun*. 2020;4:157–171
14. Yi W, Pan CQ, Li MH, Wan G, Lv YW, Liu M, et al. The characteristics and predictors of postpartum hepatitis flares in women with chronic hepatitis B. *Am J Gastroenterol*. 2018;113:686–693
15. Liu J, Wang J, Jin D, Qi C, Yan T, Cao F, et al. Hepatic flare after telbivudine withdrawal and efficacy of postpartum antiviral therapy for pregnancies with chronic hepatitis B virus. *J Gastroenterol Hepatol*. 2017;32:177–183
16. Nguyen V, Tan PK, Greenup AJ, Glass A, Davison S, Samarasinghe D, et al. Anti-viral therapy for prevention of perinatal HBV transmission: extending therapy beyond birth does not protect against post-partum flare. *Aliment Pharmacol Ther*. 2014;39:1225–1234
17. Pan CQ, Duan Z, Dai E, Zhang S, Han G, Wang Y, et al. Tenofovir to prevent hepatitis B transmission in mothers with high viral load. *N Engl J Med*. 2016;374:2324–2334
18. Jourdain G, Ngo-Giang-Huong N, Harrison L, Decker L, Khamduang W, Tierney C, et al. Tenofovir versus placebo to prevent perinatal transmission of hepatitis B. *N Engl J Med*. 2018;378:911–923
19. Chang CY, Aziz N, Poongkunran M, Javaid A, Trinh HN, Lau D, et al. Serum alanine aminotransferase and hepatitis B DNA flares in pregnant and postpartum women with chronic hepatitis B. *Am J Gastroenterol*. 2016;111:1410–1415

20. Chinese Society of Infectious Diseases CMA, Chinese Society of Hepatology CMA. The guidelines of prevention and treatment for chronic hepatitis B. version). *Zhonghua Gan Zang Bing Za Zhi*. 2019;2019(27):938–961
21. Terrault NA, Bzowej NH, Chang KM, Hwang JP, Jonas MM, Murad MH, American Association for the Study of Liver D. AASLD guidelines for treatment of chronic hepatitis B. *Hepatology* 2016;63:261–283.
22. Tan HH, Lui HF, Chow WC. Chronic hepatitis B virus (HBV) infection in pregnancy. *Hepato Int*. 2008;2:370–375
23. Chen R, Zou J, Long L, Huang H, Zhang M, Fan X, et al. Safety and efficacy of tenofovir alafenamide fumarate in early-middle pregnancy for mothers with chronic hepatitis B. *Front Med (Lausanne)*. 2021;8: 796901
24. Sarin SK, Kumar M, Lau GK, Abbas Z, Chan HL, Chen CJ, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. *Hepato Int*. 2016;10:1–98
25. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL. Clinical Practice Guidelines on the management of hepatitis B virus infection. *J Hepatol*. 2017;2017(67):370–398
26. Zhuang H. Prevention of mother-to-child transmission of hepatitis B virus. *Zhonghua Gan Zang Bing Za Zhi*. 2016;24:881–884
27. Lu Y, Zhu FC, Liu JX, Zhai XJ, Chang ZJ, Yan L, et al. The maternal viral threshold for antiviral prophylaxis of perinatal hepatitis B virus transmission in settings with limited resources: a large prospective cohort study in China. *Vaccine*. 2017;35:6627–6633
28. Liu J, Xu B, Chen T, Chen J, Feng J, Xu C, et al. Presence of hepatitis B virus markers in umbilical cord blood: exposure to or infection with the virus? *Dig Liver Dis*. 2019;51:864–869
29. Cheung KW, Seto MTY, Kan ASY, Wong D, Kou KO, So PL,